Merck Grants Exclusive License to Vertex for Two DNA Damage Re...
DARMSTADT, Germany, January 25, 2019, /PRNewswire-AsiaNet/-- Not intended for UK- or US-based media- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas - Merck retains the rights to ...
Authors: LATEST ASIANET NEWS RELEASES